Table 1. Subject characteristics and cardiovascular medication.
| CT (n = 10) | HIT (n = 10) | Control (n = 9) | ||
|---|---|---|---|---|
| Age (yrs) | 64±8 | 63±8 | 67±7 | 0.57 |
| Sex (male:female) | 10:0* | 9:1 | 5:4 | 0.028 |
| Body weight (kg) | 89.7±11.9 | 87.6±23.6 | 77.0±10.5 | 0.16 |
| Height (cm) | 177±5 | 177±3 | 174±9 | 0.66 |
| Body mass index (kg/m2) | 28.9±4.7 | 28.1±7.5 | 25.4±2.7 | 0.24 |
| NYHA class (II:III) | 8:2 | 8:2 | 8:1 | 0.84 |
| Etiology (Isch:Non-isch) | 8:2 | 7:3 | 5:4 | 0.51 |
| Systolic blood pressure (mmHg) | 132±23 | 132±18 | 130±25 | 0.98 |
| Diastolic blood pressure (mmHg) | 83±11 | 79±10 | 78±14 | 0.48 |
| Resting heart rate (/min) | 59±11 | 57±7 | 60±10 | 0.80 |
| Maximal heart rate (/min) † | 129±19 | 126±16 | 120±15 | 0.53 |
| Chronotropic incompetence (yes:no) † | 5:4 | 8:2 | 6:1 | 0.33 |
| VO2peak † (mL/min/kg) | 21.0±3.4 | 19.1±4.1 | 17.4±5.8 | 0.26 |
| VO2peak † (% of predicted VO2peak) | 86±8 | 79±17 | 81±22 | 0.63 |
| LVEF (%) | 38±6 | 37±6 | 40±11 | 0.84 |
| Medication | ||||
| Angiotensin converting enzyme-inhibitors | 5 (50%) | 6 (60%) | 8 (89%) | 0.19 |
| Angiotensin II receptor antagonists | 4 (40%) | 4 (40%) | 1 (11%) | 0.30 |
| Aldosterone antagonist | 6 (60%) | 7 (70%) | 8 (89%) | 0.36 |
| Diuretics (loopdiuretics) | 7 (70%) | 6 (60%) | 4 (44%) | 0.50 |
| β-blockers | 10 (100%) | 9 (90%) | 9 (100%) | 0.37 |
| Antiplatelet drugs | 6 (60%) | 4 (40%) | 3 (33%) | 0.47 |
| Coumarin derivates | 4 (40%) | 7 (70%) | 4 (44%) | 0.35 |
| Statins | 10 (100%) | 9 (90%) | 4 (44%) § | 0.007 |
Data is presented as mean±SD. P-values refer to a 1-way ANOVA.
† Data was unavailable for 1 subject in the CT-group and 3 subjects in the control-group.
* Significantly less females compared to the control-group.
§Lower compared to CT-group and HIT-group.